Amicus Therapeutics (FOLD) CFO exits equity as BioMarin acquisition closes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics Chief Financial Officer Simon N.R. Harford disposed of his equity in the company in connection with the consummation of its acquisition by BioMarin Pharmaceutical Inc.
The filing shows 143,595 shares of common stock were returned to the issuer at $14.50 per share, leaving Harford with zero directly held common shares. Footnotes explain that this disposition included 108,478 shares of common stock and 35,117 restricted stock units that vested in full when the merger closed.
Several stock option awards were also cancelled and converted into cash rights. Each option was exchanged for a cash payment equal to the difference between the $14.50 merger price and its exercise price, multiplied by the number of underlying shares. All reported options vested in full and, after these transactions, no stock options remain outstanding for Harford in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Harford Simon N.R.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 189,043 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 99,073 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 150,517 | $0.00 | -- |
| Disposition | Common Stock | 143,595 | $14.50 | $2.08M |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 108,478 shares of Common Stock and 35,117 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 143,595 shares at $14.50
Options at $9.41 exercise price: 150,517 option shares
Options at $14.24 exercise price: 99,073 option shares
+4 more
7 metrics
Common shares disposed
143,595 shares at $14.50
Common Stock disposition connected to merger consideration price
Options at $9.41 exercise price
150,517 option shares
Stock options cancelled and cashed out at $14.50 less $9.41
Options at $14.24 exercise price
99,073 option shares
Stock options cancelled and cashed out at $14.50 less $14.24
Options at $12.62 exercise price
189,043 option shares
Stock options cancelled and cashed out at $14.50 less $12.62
Merger per-share cash value
$14.50 per share
Cash amount used to calculate consideration for shares and options
Common shares in footnote
108,478 shares
Portion of common stock specifically identified within disposed securities
Restricted stock units vested
35,117 RSUs
RSUs that vested in full upon consummation of the merger
Key Terms
Disposition to issuer, restricted stock units, stock option, exercise price, +1 more
5 terms
Disposition to issuer financial
"transaction_code_description: "Disposition to issuer""
restricted stock units financial
"35,117 restricted stock units (which vested in full in connection with consummation of the Merger)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Merger financial
"consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
FAQ
What did Amicus Therapeutics (FOLD) CFO Simon Harford report in this Form 4?
He reported disposing of his Amicus equity in connection with the BioMarin acquisition. The filing shows common shares and stock options were returned to the issuer or cancelled, with his reported direct holdings of Amicus common stock reduced to zero after the merger.
What happened to the Amicus (FOLD) stock options held by the CFO?
Each reported stock option was cancelled at closing and converted into a cash payment. The cash amount equals the excess of the $14.50 merger price over the option’s exercise price, multiplied by the total shares subject to that option, with all such options shown as fully vested.
Does the Amicus Therapeutics (FOLD) CFO still hold options after the merger?
Based on this Form 4, the reported stock options were cancelled and converted into cash rights at the merger closing. The total shares following each derivative transaction are shown as zero, and the derivative summary is empty, indicating no remaining options in this filing.
Were the restricted stock units for Amicus (FOLD) CFO fully vested in the merger?
Yes. A footnote states that 35,117 restricted stock units vested in full in connection with consummation of the merger. These vested units are included within the common equity disposed of as part of the overall $14.50-per-share transaction with BioMarin Pharmaceutical Inc.